Omeros
About OmerosPipelineInvestorsNews


2017 Press Releases

E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle  
10/20/17Report of Successful OMS721 Treatment of Patient with Both Stem Cell Transplant-Associated Thrombotic Microangiopathy and Graft-versus-Host Disease Presented at EBMT Annual Meeting
-- Results May Expand Target for Omeros’ Planned Phase 3 Program in HCT-TMA -- SEATTLE--(BUSINESS WIRE)--Oct. 20, 2017-- Omeros Corporation (NASDAQ: OMER) today announced the presentation of a case report of a patient having co-existing hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA) and graft-versus-host disease (GvHD), which both resolved following OMS721 treatment. This case was presented this morning at t... 
 Printer Friendly Version
10/16/17Omeros Announces Upcoming Presentation of Clinical OMS721 Data at European Society for Blood and Marrow Transplantation
SEATTLE--(BUSINESS WIRE)--Oct. 16, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that data will be presented from the company’s Phase 2 clinical trial of OMS721, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), for the treatment of thrombotic microangiopathies (TMAs). The presentation will be part of the “Crash course on diagnosis and treatment of noninfectious complications a... 
 Printer Friendly Version
10/05/17Omeros Announces Settlement of Infringement Suit Against ANDA Filer Par
--Par Confirms Validity of OMIDRIA Patents and Agrees Not to Market a Generic Version of OMIDRIA Until 2032-- SEATTLE--(BUSINESS WIRE)--Oct. 5, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that it entered into a settlement agreement with Par Pharmaceutical, Inc. and its subsidiary Par Sterile Products, LLC (Par), resolving Omeros’ patent litigation against Par. The litigation concerned Par’s filing of an Abbreviated New Drug Applic... 
 Printer Friendly Version
08/23/17Omeros Responds to Statnews.com Story
SEATTLE--(BUSINESS WIRE)--Aug. 23, 2017-- Omeros Corporation (NASDAQ:OMER) stated today that it continues to pursue legal action to hold responsible those behind a series of defamatory reports about the company posted online under the pseudonym “Art Doyle,” an entity or group that self-identifies as having a short position in Omeros’ stock. Because of its ongoing legal action, including a number of steps aimed at unmasking the identity of the indi... 
 Printer Friendly Version
08/21/17Omeros Closes $68.3 Million Public Offering of Common Stock
SEATTLE--(BUSINESS WIRE)--Aug. 21, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that on August 18, 2017, as scheduled, it closed the underwritten public offering that was priced on August 14, 2017, relating to the sale of 3,000,000 shares of its common stock at a price to the public of $22.75 per share. After deducting underwriting fees and discount and other estimated offering expenses, Omeros received net proceeds from the transaction of ... 
 Printer Friendly Version
08/15/17Omeros Announces Pricing of Public Offering of Common Stock
SEATTLE--(BUSINESS WIRE)--Aug. 15, 2017-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system, announced today the pricing of its previously announced underwritten public offering of 3,000,... 
 Printer Friendly Version
08/14/17Omeros Announces Public Offering of Common Stock
SEATTLE--(BUSINESS WIRE)--Aug. 14, 2017-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system, today announced that it has commenced a registered underwritten public offering of 3,000,000 s... 
 Printer Friendly Version
08/14/17Omeros Data Show Continued Improvement in Patients with IgA Nephropathy Treated with OMS721
– Sustained Proteinuria Reduction and GFR Improvement in up to One-Year Follow-up Data – SEATTLE--(BUSINESS WIRE)--Aug. 14, 2017-- Omeros Corporation (NASDAQ: OMER) today announced additional follow-up data from patients with immunoglobulin A (IgA) nephropathy treated with OMS721 in the Phase 2 clinical trial of glomerulonephropathy. OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine prot... 
 Printer Friendly Version
08/10/17Omeros to Present at the 2017 Wedbush PacGrow Healthcare Conference
SEATTLE--(BUSINESS WIRE)--Aug. 10, 2017-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will ... 
 Printer Friendly Version
08/08/17Omeros Corporation Reports Second Quarter 2017 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE--(BUSINESS WIRE)--Aug. 8, 2017-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system, today announced recent highlights and deve... 
 Printer Friendly Version
08/04/17FDA Grants Orphan Drug Designation to Omeros’ OMS721 for Treatment of IgA Nephropathy
- Initiating Phase 3 Program for OMS721 in IgA Nephropathy with Both Breakthrough and Orphan Designations - SEATTLE--(BUSINESS WIRE)--Aug. 4, 2017-- Omeros Corporation (NASDAQ:OMER) today announced that OMS721 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of Immunoglobulin A (IgA) nephropathy. OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associ... 
 Printer Friendly Version
08/02/17Omeros Corporation to Announce Second Quarter 2017 Financial Results on August 8, 2017
SEATTLE--(BUSINESS WIRE)--Aug. 2, 2017-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter 2017 financial results for the period ended June 30, 2017, on Tuesday, August 8, 2017, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results. Conference Call Details T... 
 Printer Friendly Version
06/29/17Omeros Releases Statement in Response to Recent False Report
SEATTLE--(BUSINESS WIRE)--Jun. 29, 2017-- Omeros Corporation (NASDAQ: OMER) stated today that it is aware of a report posted on-line by “Art Doyle,” an entity or group that appears to be concealing its identity and is purportedly writing on behalf of itself or one or more employers. “Art Doyle” self-identifies as having a short position in Omeros’ stock. While the company does not routinely respond to defamatory statements, given this report’s egregious ... 
 Printer Friendly Version
06/13/17FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of IgA Nephropathy
- Omeros’ Second Phase 3 Clinical Program for OMS721 Slated to Begin this Year - SEATTLE--(BUSINESS WIRE)--Jun. 13, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to OMS721 for the treatment of Immunoglobulin A (IgA) nephropathy. OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP... 
 Printer Friendly Version
06/01/17Omeros Announces OMS721 Presentation at 54th ERA-EDTA Congress
SEATTLE--(BUSINESS WIRE)--Jun. 1, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that data from the company’s Phase 2 clinical trial of OMS721 for the treatment of Immunoglobulin A (IgA) nephropathy and other kidney diseases will be presented at the 54th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress in Madrid, Spain. The poster “The Effect of OMS721 on Proteinuria in Patients with IgA Nephropathy,” ... 
 Printer Friendly Version
05/17/17Omeros Announces Completion of IgA Nephropathy Cohort in OMS721 Phase 2 Clinical Trial
-- Additional Positive Results Support Rapid Advancement to Phase 3 Trial -- SEATTLE--(BUSINESS WIRE)--May 17, 2017-- Omeros Corporation (NASDAQ: OMER) today announced completion of the IgA nephropathy cohort and reported additional positive results from the first stage of the company’s Phase 2 clinical trial of OMS721 for the treatment of serious kidney disorders. All patients in the cohort have now completed the OMS721 treatment and follow-u... 
 Printer Friendly Version
05/10/17Omeros Corporation Reports First Quarter 2017 Financial Results
-- Conference Call Today at 4:30 p.m. ET -- SEATTLE--(BUSINESS WIRE)--May 10, 2017-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as fina... 
 Printer Friendly Version
05/03/17Omeros Corporation to Announce First Quarter 2017 Financial Results on May 10, 2017
SEATTLE--(BUSINESS WIRE)--May 3, 2017-- Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its first quarter 2017 financial results for the period ended March 31, 2017, on Wednesday, May 10, 2017, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results. Conference Call Details To ... 
 Printer Friendly Version
04/03/17Omeros to Present at the Needham Healthcare Conference
SEATTLE--(BUSINESS WIRE)--Apr. 3, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 16th Annual Needham Healthcare Conference in New York City this week. The presentation is scheduled for Wednesday, April 5, 2017 at 12:10 p.m. EDT. The presentation will be webcast. The live and archived webcasts can be accessed on the “Events” page of the comp... 
 Printer Friendly Version
03/30/17Omeros Reports More Positive Data in OMS721 Phase 2 Trial in Renal Diseases
-- Phase 3 Program Slated for This Year -- SEATTLE--(BUSINESS WIRE)--Mar. 30, 2017-- Omeros Corporation (NASDAQ: OMER) today announced additional positive data from the company’s Phase 2 clinical trial of OMS721 for the treatment of serious kidney disorders, which frequently lead to end-stage renal disease and dialysis. OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the e... 
 Printer Friendly Version
03/28/17Omeros Announces OMS721 Presentation at Annual Meeting of the European Society for Blood and Marrow Transplantation
-- Additional Positive “Challenge-Rechallenge” Data Reported in Patient with Stem Cell Transplant-Associated TMA -- SEATTLE--(BUSINESS WIRE)--Mar. 28, 2017-- Omeros Corporation (NASDAQ: OMER) today announced presentation of a case report describing resolution of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) in a dialysis- and transfusion-dependent adolescent girl who was treated with OMS721 under a compass... 
 Printer Friendly Version
03/27/17Omeros to Present Results from Dose-Ranging Stage of OMS721 Clinical Trial in Atypical Hemolytic Uremic Syndrome at World Congress of Nephrology
SEATTLE, Wash.--(BUSINESS WIRE)--Mar. 27, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that data from the dose-ranging stage of the Phase 2 clinical trial evaluating OMS721 in the treatment of atypical hemolytic uremic syndrome (aHUS) will be presented next month at the International Society of Nephrology’s World Congress of Nephrology in Mexico City. The poster presentation, “Dose-Finding Clinical Trial of OMS721 for the Treatment of Atypica... 
 Printer Friendly Version
03/16/17Omeros Corporation Reports Fourth Quarter and Year-End 2016 Financial Results
-- Conference Call Today at 4:30 p.m. ET -- SEATTLE--(BUSINESS WIRE)--Mar. 16, 2017-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as fin... 
 Printer Friendly Version
03/10/17Omeros Corporation to Announce Fourth Quarter and Year-End 2016 Financial Results on March 16, 2017
SEATTLE--(BUSINESS WIRE)--Mar. 10, 2017-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end 2016 financial results for the period ended December 31, 2016, on Thursday, March 16, 2017, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results. Conference Call Detai... 
 Printer Friendly Version
03/02/17Omeros to Present at the Cowen and Company Annual Health Care Conference
SEATTLE--(BUSINESS WIRE)--Mar. 2, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA next week. The presentation is scheduled for Tuesday, March 7, 2017 at 10:40 a.m. EST. The presentation will be webcast. The live and archived webcasts can be accessed on the “Events” page of th... 
 Printer Friendly Version
03/01/17Omeros Reports Additional Positive Results from OMS721 Phase 2 Trial in Patients with Stem Cell Transplant-Associated Thrombotic Microangiopathy
--Data Presented at the Recent Combined International and American Blood & Marrow Transplantation Meetings-- SEATTLE--(BUSINESS WIRE)--Mar. 1, 2017-- Omeros Corporation (NASDAQ: OMER) today announced additional positive data from the ongoing Phase 2 clinical trial evaluating OMS721 in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA). These data were presented at the combined annual meeting... 
 Printer Friendly Version